Literature DB >> 8148275

Increased serum and blister fluid levels of creatine kinase in patients with toxic epidermal necrolysis.

F Caux1, O Chosidow, C Philippon, J C Roujeau, J Revuz.   

Abstract

Keratinocytes have recently been reported to contain creatine kinase (CK) of brain-type isoenzyme. The aim of this study was to investigate whether necrosis of keratinocytes induced raised CK levels in toxic epidermal necrolysis (TEN). The serum and blister fluid levels of creatine kinase and its isoenzymes [muscular-type (MM), brain-type (BB), myocardial-type (MB)] were measured in 40 patients with TEN, 10 patients with other bullous dermatoses, and in suction blisters in five controls. The mean serum CK was significantly higher in TEN patients than in patients with other bullous dermatoses (mean +/- SD: 480 +/- 535 U/l vs. 107 +/- 44 U/l, P < 0.05). The MM-isoenzyme was predominant (94%). A positive correlation was found between the level of the serum CK and the percentage of body surface area (BSA) involved (r = 0.49, P < 0.001). The mean blister CK was significantly higher in TEN patients than in patients with other bullous dermatoses or controls (mean +/- SD: 728 +/- 437 U/l vs. 310 +/- 244 U/l and 268 +/- 194 U/l, respectively, P < 0.02). The isoenzyme distribution of blister CK in TEN patients was: 76.8% MM, 18.1% MB and 5% BB. Although a significant part of blister CK comigrating with CK-MB, after preincubation with protein A-Sepharose, appeared to be CK-BB/IgG complex, the CK-BB fraction constituted less than 25% of blister CK. Therefore, the CK present in increased amounts in serum and blister fluid in TEN was not directly produced by keratinocytes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8148275     DOI: 10.1111/j.1365-2133.1994.tb02930.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  1 in total

1.  Association of creatine kinase and skin toxicity in phase I trials of anticancer agents.

Authors:  V Moreno Garcia; P Thavasu; M Blanco Codesido; L R Molife; J Vitfell Pedersen; M Puglisi; B Basu; K Shah; J Iqbal; J S de Bono; S B Kaye; U Banerji
Journal:  Br J Cancer       Date:  2012-10-25       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.